Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical toolsMALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: STIM), a ...

suggesting that TMS functions as a comprehensive treatment rather than targeting specific symptoms. The analysis, which included 578 patients with major depressive disorder, showed equal ...

Several small studies have indicated that low-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS ... the effectiveness of this treatment in clinical practice has ...

These publications further cement NeuroStar’s position as the leader in advancing TMS therapy and shaping the future of depression treatment.” The following publications highlight key findings ...

TMS is also referred to as repetitive transcranial magnetic stimulation or rTMS. TMS offers a treatment option for people suffering from various mental and neurological disorders, particularly ...

"NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

TRICARE recently announced coverage of Transcranial Magnetic Stimulation (TMS) as a treatment for major depressive disorder. TMS is used when other depression treatments have not been effective.

This approval marks NeuroStar as the first and only transcranial magnetic stimulation (TMS) therapy cleared by the FDA for use in this younger demographic, expanding its indications to a fourth ...